Cell-penetrating peptides as versatile vehicles for oligonucleotide delivery

Molecular Therapy

Volumn 20, Issue 3, 2012, Pages 525-533

  Margus, Helerin ^a   Padari, Kärt ^a   Pooga, Margus ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PENETRATING PEPTIDE; HYDROXYPROLINE; MONOMER; OLIGONUCLEOTIDE; PLASMID DNA; SMALL INTERFERING RNA; SPLICING CORRECTION OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN;

AMINO ACID SEQUENCE; CELL ACTIVITY; CELL MEMBRANE PERMEABILITY; ENZYME DEGRADATION; GENE DELIVERY SYSTEM; GENE EXPRESSION REGULATION; GENE SILENCING; GENE VECTOR; GENETIC ANALYSIS; HUMAN; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OLIGONUCLEOTIDE THERAPY; REVIEW; RNA INTERFERENCE; RNA SPLICING; SENSITIVITY AND SPECIFICITY;

EID: 84857781844     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.284     Document Type: Review

References (95)

1. Whitehead, KA, Langer, R and Anderson, DG (2009). Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8: 129-138.
2. Wood, MJ (2010). Toward an oligonucleotide therapy for Duchenne muscular dystrophy: a complex development challenge. Sci Transl Med 2: 25ps15.
3. Zuhorn, IS, Engberts, JB and Hoekstra, D (2007). Gene delivery by cationic lipid vectors: overcoming cellular barriers. Eur Biophys J 36: 349-362. (Pubitemid 46626209)
4. Wang, Y, Li, Z, Han, Y, Liang, LH and Ji, A (2010). Nanoparticle-based delivery system for application of siRNA in vivo. Curr Drug Metab 11: 182-196.
5. Nakamura, Y, Kogure, K, Futaki, S and Harashima, H (2007). Octaarginine-modified multifunctional envelope-type nano device for siRNA. J Control Release 119: 360-367. (Pubitemid 46770881)
6. Ivanova, GD, Arzumanov, A, Abes, R, Yin, H, Wood, MJ, Lebleu, B et al. (2008). Improved cell-penetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 36: 6418-6428.
7. Hassane, FS, Ivanova, GD, Bolewska-Pedyczak, E, Abes, R, Arzumanov, AA, Gait, MJ et al. (2009). A peptide-based dendrimer that enhances the splice-redirecting activity of PNA conjugates in cells. Bioconjug Chem 20: 1523-1530.
8. Mäe, M, El Andaloussi, S, Lundin, P, Oskolkov, N, Johansson, HJ, Guterstam, P et al. (2009). A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 134: 221-227.
9. Trabulo, S, Resina, S, Simões, S, Lebleu, B and Pedroso de Lima, MC (2010). A noncovalent strategy combining cationic lipids and CPPs to enhance the delivery of splice correcting oligonucleotides. J Control Release 145: 149-158.
10. Lehto, T, Abes, R, Oskolkov, N, Suhorutsenko, J, Copolovici, DM, Mäger, I et al. (2010). Delivery of nucleic acids with a stearylated (RxR)4 peptide using a noncovalent co-incubation strategy. J Control Release 141: 42-51.
11. Andaloussi, SE, Lehto, T, Mäger, I, Rosenthal-Aizman, K, Oprea, II, Simonson, OE et al. (2011). Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res 39: 3972-3987.
12. Ezzat, K, Andaloussi, SE, Zaghloul, EM, Lehto, T, Lindberg, S, Moreno, PM et al. (2011). PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. Nucleic Acids Res 39: 5284-5298.
13. Eguchi, A, Meade, BR, Chang, YC, Fredrickson, CT, Willert, K, Puri, N et al. (2009). Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein. Nat Biotechnol 27: 567-571.
14. Crombez, L, Morris, MC, Dufort, S, Aldrian-Herrada, G, Nguyen, Q, Mc Master, G et al. (2009). Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 37: 4559-4569.
15. Deshayes, S, Gerbal-Chaloin, S, Morris, MC, Aldrian-Herrada, G, Charnet, P, Divita, G et al. (2004). On the mechanism of non-endosomial peptide-mediated cellular delivery of nucleic acids. Biochim Biophys Acta 1667: 141-147. (Pubitemid 39576077)
16. Konate, K, Crombez, L, Deshayes, S, Decaffmeyer, M, Thomas, A, Brasseur, R et al. (2010). Insight into the cellular uptake mechanism of a secondary amphipathic cellpenetrating peptide for siRNA delivery. Biochemistry 49: 3393-3402.
17. Rydström, A, Deshayes, S, Konate, K, Crombez, L, Padari, K, Boukhaddaoui, H et al. (2011). Direct translocation as major cellular uptake for CADY self-assembling peptide-based nanoparticles. PLoS ONE 6: e25924.
18. Lundin, P, Johansson, H, Guterstam, P, Holm, T, Hansen, M, Langel, O et al. (2008). Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem 19: 2535-2542.
19. Wadia, JS, Stan, RV and Dowdy, SF (2004). Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10: 310-315. (Pubitemid 38667624)
20. Lundberg, P, El-Andaloussi, S, Sütlü, T, Johansson, H and Langel, O (2007). Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J 21: 2664-2671. (Pubitemid 47372734)
21. El-Sayed, A, Futaki, S and Harashima, H (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11: 13-22.
22. Morris, MC, Vidal, P, Chaloin, L, Heitz, F and Divita, G (1997). A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25: 2730-2736. (Pubitemid 27299785)
23. Järver, P and Langel O (2004). The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9: 395-402. (Pubitemid 38479684)
24. Zatsepin, TS, Turner, JJ, Oretskaya, TS and Gait, MJ (2005). Conjugates of oligonucleotides and analogues with cell penetrating peptides as gene silencing agents. Curr Pharm Des 11: 3639-3654. (Pubitemid 41630990)
25. Morris, MC, Gros, E, Aldrian-Herrada, G, Choob, M, Archdeacon, J, Heitz, F et al. (2007). A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 35: e49.
26. Muratovska, A and Eccles, MR (2004). Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 558: 63-68. (Pubitemid 38167411)
27. Stephenson, ML and Zamecnik, PC (1978). Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci USA 75: 285-288. (Pubitemid 8290784)
28. Crooke, ST (2004). Antisense strategies. Curr Mol Med 4: 465-487. (Pubitemid 38961192)
29. de Martimprey, H, Vauthier, C, Malvy, C and Couvreur, P (2009). Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA. Eur J Pharm Biopharm 71: 490-504.
30. Morris, MC, Chaloin, L, Choob, M, Archdeacon, J, Heitz, F and Divita, G (2004). Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 11: 757-764. (Pubitemid 38659754)
31. Efimov, V, Choob, M, Buryakova, A, Phelan, D and Chakhmakhcheva, O (2001). PNA-related oligonucleotide mimics and their evaluation for nucleic acid hybridization studies and analysis. Nucleosides Nucleotides Nucleic Acids 20: 419-428. (Pubitemid 32821807)
32. Morris, MC, Depollier, J, Mery, J, Heitz, F and Divita, G (2001). A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19: 1173-1176. (Pubitemid 33115705)
33. Veronese, FM and Pasut, G (2005). PEGylation, successful approach to drug delivery. Drug Discov Today 10: 1451-1458. (Pubitemid 41483874)
34. Faustino, NA and Cooper, TA (2003). Pre-mRNA splicing and human disease. Genes Dev 17: 419-437. (Pubitemid 36258756)
35. Sazani, P and Kole, R (2003). Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 112: 481-486. (Pubitemid 38056330)
36. Dominski, Z and Kole, R (1993). Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 90: 8673-8677. (Pubitemid 23277732)
37. Kang, SH, Cho, MJ and Kole, R (1998). Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 37: 6235-6239. (Pubitemid 28213640)
38. Astriab-Fisher, A, Sergueev, D, Fisher, M, Shaw, BR and Juliano, RL (2002). Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. Pharm Res 19: 744-754. (Pubitemid 34686732)
39. Moulton, HM and Moulton, JD (2003). Peptide-assisted delivery of steric-blocking antisense oligomers. Curr Opin Mol Ther 5: 123-132. (Pubitemid 36626452)
40. El-Andaloussi, S, Johansson, HJ, Lundberg, P and Langel O (2006). Induction of splice correction by cell-penetrating peptide nucleic acids. J Gene Med 8: 1262-1273. (Pubitemid 44660525)
41. Futaki, S, Ohashi, W, Suzuki, T, Niwa, M, Tanaka, S, Ueda, K et al. (2001). Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem 12: 1005-1011. (Pubitemid 33136872)
42. Khalil, IA, Futaki, S, Niwa, M, Baba, Y, Kaji, N, Kamiya, H et al. (2004). Mechanism of improved gene transfer by the N-terminal stearylation of octaarginine: enhanced cellular association by hydrophobic core formation. Gene Ther 11: 636-644. (Pubitemid 38455982)
43. Tönges, L, Lingor, P, Egle, R, Dietz, GP, Fahr, A and Bähr, M (2006). Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. RNA 12: 1431-1438. (Pubitemid 43990566)
44. Rothbard, JB, Kreider, E, VanDeusen, CL, Wright, L, Wylie, BL and Wender, PA (2002). Arginine-rich molecular transporters for drug delivery: role of backbone spacing in cellular uptake. J Med Chem 45: 3612-3618. (Pubitemid 34856101)
45. Ramsay, E and Gumbleton, M (2002). Polylysine and polyornithine gene transfer complexes: a study of complex stability and cellular uptake as a basis for their differential in-vitro transfection efficiency. J Drug Target 10: 1-9. (Pubitemid 34223844)
46. Oskolkov, N, Arukuusk, P, Copolovici, DM, Lindberg, S, Margus, H, Padari, K et al. (2011). NickFects, phosphorylated derivatives of transportan 10 for cellular delivery of oligonucleotides. Int J Pept Res Ther 17: 147-157.
47. Hammond, SM, Bernstein, E, Beach, D and Hannon, GJ (2000). An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404: 293-296. (Pubitemid 30163547)
48. Matranga, C, Tomari, Y, Shin, C, Bartel, DP and Zamore, PD (2005). Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes. Cell 123: 607-620. (Pubitemid 41608464)
49. Zamore, PD, Tuschl, T, Sharp, PA and Bartel, DP (2000). RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33.
50. Simeoni, F, Morris, MC, Heitz, F and Divita, G (2003). Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 31: 2717-2724. (Pubitemid 37442116)
51. Zeineddine, D, Papadimou, E, Chebli, K, Gineste, M, Liu, J, Grey, C et al. (2006). Oct-3/4 dose dependently regulates specification of embryonic stem cells toward a cardiac lineage and early heart development. Dev Cell 11: 535-546. (Pubitemid 44430895)
52. Veldhoen, S, Laufer, SD, Trampe, A and Restle, T (2006). Cellular delivery of small interfering RNA by a non-covalently attached cell-penetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 34: 6561-6573. (Pubitemid 46017951)
53. Kogure, K, Moriguchi, R, Sasaki, K, Ueno, M, Futaki, S and Harashima, H (2004). Development of a non-viral multifunctional envelope-type nano device by a novel lipid film hydration method. J Control Release 98: 317-323. (Pubitemid 38950740)
54. Sasaki, K, Kogure, K, Chaki, S, Kihira, Y, Ueno, M and Harashima, H (2005). Construction of a multifunctional envelope-type nano device by a SUV*-fusion method. Int J Pharm 296: 142-150. (Pubitemid 40693383)
55. Moriguchi, R, Kogure, K, Akita, H, Futaki, S, Miyagishi, M, Taira, K et al. (2005). A multifunctional envelope-type nano device for novel gene delivery of siRNA plasmids. Int J Pharm 301: 277-285. (Pubitemid 41206613)
56. Nakamura, Y, Kogure, K, Yamada, Y, Futaki, S and Harashima, H (2006). Significant and prolonged antisense effect of a multifunctional envelope-type nano device encapsulating antisense oligodeoxynucleotide. J Pharm Pharmacol 58: 431-437.
57. Khalil, IA, Kogure, K, Futaki, S, Hama, S, Akita, H, Ueno, M et al. (2007). Octaargininemodified multifunctional envelope-type nanoparticles for gene delivery. Gene Ther 14: 682-689. (Pubitemid 46585628)
58. Sakurai, Y, Hatakeyama, H, Sato, Y, Akita, H, Takayama, K, Kobayashi, S et al. (2011). Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA. Biomaterials 32: 5733-5742.
59. Kim, WJ, Christensen, LV, Jo, S, Yockman, JW, Jeong, JH, Kim, YH et al. (2006). Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 14: 343-350. (Pubitemid 44184964)
60. Kumar, P, Wu, H, McBride, JL, Jung, KE, Kim, MH, Davidson, BL et al. (2007). Transvascular delivery of small interfering RNA to the central nervous system. Nature 448: 39-43. (Pubitemid 47037001)
61. Lentz, TL, Burrage, TG, Smith, AL, Crick, J and Tignor, GH (1982). Is the acetylcholine receptor a rabies virus receptor? Science 215: 182-184. (Pubitemid 12178107)
62. Lafon, M (2005). Rabies virus receptors. J Neurovirol 11: 82-87. (Pubitemid 40458377)
63. Rittner, K, Benavente, A, Bompard-Sorlet, A, Heitz, F, Divita, G, Brasseur, R et al. (2002). New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 5: 104-114. (Pubitemid 34144826)
64. Crombez, L, Aldrian-Herrada, G, Konate, K, Nguyen, QN, McMaster, GK, Brasseur, R et al. (2009). A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 17: 95-103.
65. Derossi, D, Joliot, AH, Chassaing, G and Prochiantz, A (1994). The third helix of the Antennapedia homeodomain translocates through biological membranes. J Biol Chem 269: 10444-10450. (Pubitemid 24198241)
66. Vivès, E, Brodin, P and Lebleu, B (1997). A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017. (Pubitemid 27265584)
67. Deshayes, S, Heitz, A, Morris, MC, Charnet, P, Divita, G and Heitz, F (2004). Insight into the mechanism of internalization of the cell-penetrating carrier peptide Pep-1 through conformational analysis. Biochemistry 43: 1449-1457. (Pubitemid 38200550)
68. Mano, M, Teodósio, C, Paiva, A, Simões, S and Pedroso de Lima, MC (2005). On the mechanisms of the internalization of S4(13)-PV cell-penetrating peptide. Biochem J 390(Pt 2): 603-612. (Pubitemid 41337122)
69. Duchardt, F, Fotin-Mleczek, M, Schwarz, H, Fischer, R and Brock, R (2007). A comprehensive model for the cellular uptake of cationic cell-penetrating peptides. Traffic 8: 848-866. (Pubitemid 46971632)
70. Fretz, MM, Penning, NA, Al-Taei, S, Futaki, S, Takeuchi, T, Nakase, I et al. (2007). Temperature-, concentration-and cholesterol-dependent translocation of L-and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J 403: 335-342. (Pubitemid 46596590)
71. Jiao, CY, Delaroche, D, Burlina, F, Alves, ID, Chassaing, G and Sagan, S (2009). Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem 284: 33957-33965.
72. Säälik, P, Niinep, A, Pae, J, Hansen, M, Lubenets, D, Langel, Ü et al. (2011). Penetration without cells: membrane translocation of cell-penetrating peptides in the model giant plasma membrane vesicles. J Control Release 153: 117-125.
73. Vives, E (2005). Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J Control Release 109: 77-85. (Pubitemid 41737254)
74. Ryser, HJ and Shen, WC (1978). Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 75: 3867-3870. (Pubitemid 8399303)
75. Nakase, I, Tadokoro, A, Kawabata, N, Takeuchi, T, Katoh, H, Hiramoto, K et al. (2007). Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 46: 492-501. (Pubitemid 46105438)
76. Ziegler, A and Seelig, J (2008). Binding and clustering of glycosaminoglycans: a common property of mono-and multivalent cell-penetrating compounds. Biophys J 94: 2142-2149.
77. Gerbal-Chaloin, S, Gondeau, C, Aldrian-Herrada, G, Heitz, F, Gauthier-Rouvière, C and Divita, G (2007). First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol Cell 99: 223-238. (Pubitemid 46567179)
78. Hassane, FS, Abes, R, El Andaloussi, S, Lehto, T, Sillard, R, Langel O et al. (2011). Insights into the cellular trafficking of splice redirecting oligonucleotides complexed with chemically modified cell-penetrating peptides. J Control Release 153: 163-172.
79. Muñoz-Morris, MA, Heitz, F, Divita, G and Morris, MC (2007). The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun 355: 877-882. (Pubitemid 46366909)
80. Crombez, L, Charnet, A, Morris, MC, Aldrian-Herrada, G, Heitz, F and Divita, G (2007). A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans 35(Pt 1): 44-46.
81. Räägel, H, Säälik, P, Hansen, M, Langel O and Pooga, M (2009). CPP-protein constructs induce a population of non-acidic vesicles during trafficking through endolysosomal pathway. J Control Release 139: 108-117.
82. Parton, RG and Richards, AA (2003). Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 4: 724-738. (Pubitemid 37361854)
83. Sabharanjak, S, Sharma, P, Parton, RG and Mayor, S (2002). GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell 2: 411-423. (Pubitemid 34436571)
84. Palm-Apergi, C, Lorents, A, Padari, K, Pooga, M and Hällbrink, M (2009). The membrane repair response masks membrane disturbances caused by cell-penetrating peptide uptake. FASEB J 23: 214-223.
85. Padari, K, Koppel, K, Lorents, A, Hällbrink, M, Mano, M, Pedroso de Lima, MC et al. (2010). S4(13)-PV cell-penetrating peptide forms nanoparticle-like structures to gain entry into cells. Bioconjug Chem 21: 774-783.
86. Herce, HD and Garcia, AE (2007). Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci USA 104: 20805-20810.
87. Gruenberg, J (2001). The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 2: 721-730. (Pubitemid 33679834)
88. Maxfield, FR and McGraw, TE (2004). Endocytic recycling. Nat Rev Mol Cell Biol 5: 121-132. (Pubitemid 38160255)
89. Endoh, T and Ohtsuki, T (2009). Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 61: 704-709.
90. Nakase, I, Kobayashi, S and Futaki, S (2010). Endosome-disruptive peptides for improving cytosolic delivery of bioactive macromolecules. Biopolymers 94: 763-770.
91. Johnson, RM, Harrison, SD and Maclean, D (2011). Therapeutic applications of cell-penetrating peptides. Methods Mol Biol 683: 535-551.
92. Waugh, JM, Lee, J, Dake, MD and Browne, D (2011). Nonclinical and clinical experiences with CPP-based self-assembling peptide systems in topical drug development. Methods Mol Biol 683: 553-572.
93. van den Berg, A and Dowdy, SF (2011). Protein transduction domain delivery of therapeutic macromolecules. Curr Opin Biotechnol 22: 888-893.
94. Watts, JK and Corey, DR (2012). Silencing disease genes in the laboratory and the clinic. J Pathol 226: 365-379.
95. Moulton, HM and Moulton, JD (2010). Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 1798: 2296-2303.